Gozgit et al. confirmed that inhibition of FGFR2 and mTOR activity, by combined oral treatment of both AP24534 and ridaforolimus in nude mice, exerted a synergistic antitumor effect in an endometrial cancer xenograft model [32]. This evidence concerns the gene FGFR2 and endometrial cancer.